RxNorm Names
GENTEAL MILD TO MODERATE
(hypromellose)
liquid
[Novartis Pharmaceutical Corporation]
Permanent Link:
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=dfcc80aa-aee3-4e9a-b844-12ffcd872cae| Category | DEA Schedule | Marketing Status |
|---|---|---|
| HUMAN OTC DRUG LABEL | OTC monograph final |
NOTE:MOST OTC DRUGS ARE NOT REVIEWED AND APPROVED BY FDA, HOWEVER THEY MAY BE MARKETED IF THEY COMPLY WITH APPLICABLE REGULATIONS AND POLICIES. FDA HAS NOT EVALUATED WHETHER THIS PRODUCT COMPLIES.
INDICATIONS & USAGE SECTION
- Relieves dryness of the eye.
- Temporarily relieves discomfort due to minor irritations of the eye or from exposure to wind and sun.
- As a protectant against further irritation.
OTC - DO NOT USE SECTION
Do not use
- if solution changes color or becomes cloudy
- if you are sensitive to any ingredient in this product
OTC - WHEN USING SECTION
When using this product do not touch tip of container to any surface. Replace cap after using.
OTC - STOP USE SECTION
Stop use and ask a doctor if you experience any of the following:
- eye pain
- changes in vision
- continued redness or irritation of the eye
- condition worsens or persists for more than 72 hours
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
INACTIVE INGREDIENT SECTION
Boric acid, phosphonic acid, potassium chloride, purified water, sodium chloride and sodium perborate. May contain hydrochloric acid and / or sodium hydroxide to adjust pH.
| GENTEAL
MILD TO MODERATE
hypromellose liquid |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - Novartis Pharmaceutical Corporation (002147023) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
| EXCELVISION AG | 482198285 | MANUFACTURE(0078-0518) | |
Revised: 09/2012
Document Id: f9a7c50d-feb8-375d-cc86-1a779df24eea
Set id: dfcc80aa-aee3-4e9a-b844-12ffcd872cae
Version: 3
Effective Time: 20120917
Novartis Pharmaceutical Corporation
Review RxNorm Normal Forms